FY27 Guidance Upgraded to ₹725 Cr – ₹750 Cr Revenue & ₹210 Cr – ₹225 Cr Net Profit

Mumbai: Cupid Limited (“Cupid” or “the Company”), Bharat’s rapidly growing consumer wellness and personal care company with a strong global healthcare franchise, announced its financial results for the quarter ended 30th June, 2026. Supported by continued business momentum and improved visibility across its healthcare and consumer businesses.

Key Consolidated Financial Highlights

Q1 FY27 (YoY)

  • Total Income of ₹ 156.98 Cr, YoY growth of 142%
  • Operating Income of ₹ 154.72 Cr, YoY growth of 159%
  • EBITDA of ₹ 60.06 Cr, YoY growth of 265%
  • EBITDA Margin of 39%, YoY growth of 1,127 Bps
  • Net Profit of ₹ 44.14 Cr, YoY growth of 194%
  • Net Profit Margin of 29%, YoY growth of 344 Bps
  • EPS of ₹ 0.32, YoY growth of 220%

Q1 FY27 (QoQ)

  • Total Income of ₹ 156.98 Cr, QoQ growth of 19%
  • Operating Income of ₹ 154.72 Cr, QoQ growth of 29%
  • EBITDA of ₹ 60.06 Cr, QoQ growth of 60%
  • EBITDA Margin of 39%, QoQ growth of 755 Bps
  • Net Profit of ₹ 44.14 Cr, QoQ growth of 22%
  • Net Profit Margin of 29%
  • EPS of ₹ 0.32, QoQ growth of 23%

Strong Start To FY27

  • Cupid commenced FY27 with strong momentum across its international B2B healthcare and domestic Consumer Healthcare & FMCG businesses, supported by healthy execution across key operating segments.
  • The Company’s international B2B healthcare business continued to witness robust demand across PFSCM, WHO/UNFPA, institutional procurement programmes, government tenders and private export markets, providing strong order visibility and a healthy revenue pipeline.
  • Strong growth in operating income reflects the increasing contribution of the Company’s core operating businesses, reinforcing the quality of earnings and the sustainability of its growth trajectory.
  • The Company expects sizeable orders across its IVD Kits portfolio from multiple State Governments in India, along with significant international opportunities following the receipt of CE certifications. Several opportunities are in the final stages of the award process, providing a strong near-term growth pipeline.
  • The Company has implemented a minimum 10% price increase across its export portfolio, supporting improved realizations and margin expansion.
  • A favourable USD/INR environment has supported export realizations, while prudent hedging of currency exposure relating to international investments helps mitigate foreign exchange risk.
  • Supported by a strong order book, expanding Consumer Healthcare & FMCG portfolio, healthy international B2B demand and expectations of robust performance during the second half of FY27, the Company has enhanced its FY27 guidance to ₹725 Cr – ₹750 Cr in revenue and ₹210 Cr – ₹ 225 Cr in Net Profit, reinforcing confidence in its long-term growth trajectory.
  • During FY26, the Company’s Consumer Healthcare & FMCG portfolio contributed revenue of ₹121.61 crore, comprising domestic sales of male and female condoms, IVD kits, personal lubricants and newly launched FMCG products, including ₹84.26 crore from the newly launched FMCG portfolio.

Commenting on the performance, Mr. Aditya Kumar Halwasiya, Chairman and Managing Director, Cupid Limited, said: “We have commenced FY27 with strong momentum across both our international B2B healthcare and Consumer Healthcare & FMCG businesses. Healthy execution during the quarter, improving order visibility and sustained demand across our core segments have strengthened our confidence in the Company’s growth trajectory. Supported by a robust order book, healthy business momentum and strong visibility across our key operating segments, we have enhanced our FY27 guidance to ₹725 Cr – ₹750 Cr in revenue and ₹210 Cr – ₹225 Cr in Net Profit.

Our Consumer Healthcare & FMCG business continues to gain meaningful traction and remains an important pillar of our long-term growth strategy. During the quarter, the business witnessed encouraging momentum across our diversified portfolio, supported by growing consumer acceptance and an expanding presence across modern trade, organised retail and pharmacy channels. We continue to strengthen our market penetration through a broad portfolio spanning domestic male and female condoms, IVD kits, personal lubricants and an expanding range of personal care and wellness products, positioning the business for sustainable long-term growth.

Our international B2B healthcare business continues to demonstrate healthy momentum, supported by strong demand across PFSCM, WHO/UNFPA and other institutional procurement programmes, government tenders and private export markets. This diversified order pipeline provides strong revenue visibility and reinforces our leadership across global healthcare markets. The commissioning of our Palava manufacturing facility during Q2 FY27 will further strengthen our manufacturing flexibility, enhance supply capabilities and support future growth across both international healthcare and domestic Consumer Healthcare & FMCG businesses. We also expect our strategic investments to be value accretive for the Company over FY27 and beyond, further strengthening our long-term growth platform. Looking ahead, we remain focused on disciplined execution, maintaining healthy margins and building a future-ready organisation through continued investments in manufacturing, product innovation, international B2B healthcare and Consumer Healthcare & FMCG businesses. We believe these strategic initiatives position Cupid to deliver sustainable long-term growth and create enduring value for all our stakeholders.”